ALSO READJ&J reports quarterly loss on $13.6 billion tax charge Abbott's fourth-quarter results, 2018 profit forecast beat estimates Abbott results beat on strong medical device business Abbott to take a pause after deal spree Cabinet approves MoU between India and Cuba on cooperation in the field of Health and Medicine
(Reuters) - Johnson & Johnson reported a better-than-expected first-quarter profit on Tuesday and raised its full-year sales forecast, helped by growing demand for its cancer drugs.
J&J raised its full-year sales forecast to $81.0 billion to $81.8 billion from its previous forecast of $80.6 billion to $81.4 billion.
Sales in the first quarter jumped to $20.01 billion from $17.77 billion a year earlier, beating analysts' estimates of $19.46 billion.
Net earnings fell to $4.37 billion, or $1.60 per share, from $4.42 billion, or $1.61 per share, a year earlier.
Shares in the Dow-component were up 1.1 percent to $133.25 before the bell.
(Reporting by Manas Mishra in Bengaluru; Editing by Supriya Kurane)
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)